Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy
NCT01514149 on ClinicalTrials.gov · last registry update 2017-07-19
Stopped early, having planned 73 participants. The sponsor logged completion for May 2012. Primary outcome, as filed: Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- TERMINATED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- ConjuChem
- Sponsor type
- Industry
- Enrollment
- 73
- Started
- 2011-09
- Primary completion
- 2012-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Glycosylated Hemoglobin Change From Baseline (CFB) to Week 18
Conditions studied
Type 2 Diabetes Mellitus (T2DM)
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.